Global Blood Screening Market Size By Type (Reagent, Instrument), By Application (Blood Bank, Hospital), By Region, And Segment Forecasts, 2023 to 2032

lobal Blood Screening Market Report Description

The Global Blood Screening Market was valued at USD 3.9 billion in 2023 and is projected to reach USD 7.2 billion by 2031, growing at a CAGR of 7.8% during the forecast period (2023–2031). The market growth is driven by the rising prevalence of infectious diseases, increasing demand for safe blood transfusions, and technological advancements in screening techniques such as nucleic acid testing (NAT) and ELISA-based assays.

Blood screening is a critical step in ensuring the safety of blood donations by detecting infectious agents like HIV, hepatitis B and C, syphilis, and Zika virus. With growing awareness of transfusion-transmitted infections (TTIs) and stringent regulatory guidelines across healthcare systems, the adoption of advanced blood screening technologies is accelerating globally.

Drivers

Increasing Incidence of Transfusion-Transmitted Infections (TTIs)

The growing cases of TTIs have heightened the need for advanced screening solutions. Governments and healthcare institutions are mandating rigorous testing protocols, driving market expansion.

Technological Advancements in Screening Techniques

The shift from traditional serology to highly sensitive molecular diagnostic tests, such as NAT, enhances detection accuracy and reduces the window period for infection identification.

Rising Demand for Safe Blood and Blood Products

With an increase in surgical procedures, trauma cases, and cancer treatments requiring transfusions, the demand for reliable blood screening methods is surging.

Restraints

High Cost of Advanced Screening Technologies

NAT and other molecular tests require sophisticated infrastructure, making them less affordable for low-resource regions.

Lack of Skilled Personnel

The operation of advanced screening platforms requires trained technicians, which remains a challenge in emerging economies.

Opportunity

Growing Adoption in Emerging Economies

Expanding healthcare infrastructure in Asia-Pacific, Latin America, and Africa provides significant opportunities for blood screening vendors.

Integration of Automation and AI

The introduction of AI-enabled automated platforms for blood screening can improve throughput, reduce human error, and enhance overall testing efficiency.

Market by System Type Insights

Based on system type, Nucleic Acid Testing (NAT) systems accounted for the largest market share in 2023. Their superior sensitivity and ability to detect infections during the early window period make them the preferred screening method. However, ELISA-based immunoassays remain widely used in cost-sensitive regions due to their affordability and ease of implementation.

Market by End-use Insights

In terms of end-use, blood banks dominated the market in 2023, accounting for more than 45% of the revenue share, as they are the primary hubs for blood collection and testing. Hospitals and diagnostic centers are also rapidly adopting advanced screening technologies to ensure the safety of transfusions.

Market by Regional Insights

North America led the global blood screening market in 2023 due to well-established healthcare infrastructure, stringent regulatory guidelines, and the presence of leading market players.

Asia-Pacific is expected to witness the highest growth rate during the forecast period, driven by rising awareness of blood safety, increasing healthcare spending, and supportive government initiatives in countries like India and China.

Europe maintains a significant market share due to advanced healthcare systems and mandatory screening protocols.

Competitive Scenario

Key players in the Global Blood Screening Market include Roche Diagnostics, Abbott Laboratories, Grifols S.A., Bio-Rad Laboratories, Thermo Fisher Scientific, Siemens Healthineers, Ortho Clinical Diagnostics, Danaher Corporation, and BD (Becton Dickinson and Company).

Leading companies are focusing on strategic partnerships, automation, AI integration, and expanding test menus for broader pathogen detection.

Recent Developments:

2024: Abbott launched a fully automated NAT platform with integrated AI analytics for faster and more accurate screening.

2023: Roche Diagnostics received regulatory approval for its next-generation multiplex NAT assay covering multiple infectious diseases in a single test.

2023: Grifols expanded its blood screening reagent manufacturing capacity to meet rising global demand.

Scope of Work – Global Blood Screening Market

Key Market Developments

July 2024: Abbott introduced a cost-effective NAT platform tailored for low-resource settings in Asia and Africa.

May 2023: Roche launched an AI-powered ELISA reader to improve workflow efficiency in blood banks.

February 2023: Grifols partnered with leading diagnostic centers in Europe to expand access to multiplex NAT assays.

FAQs

What is the current market size of the Global Blood Screening Market?

The market was valued at USD 3.9 billion in 2023.

What is the major growth driver of the Global Blood Screening Market?

The rising prevalence of transfusion-transmitted infections and demand for safe blood transfusions are key drivers.

Which is the largest region during the forecast period in the Global Blood Screening Market?

North America holds the largest share due to strict regulatory frameworks and advanced healthcare infrastructure.

Which segment accounted for the largest market share in the Global Blood Screening Market?

Nucleic Acid Testing (NAT) dominated due to its superior accuracy and early infection detection capability.

Who are the key market players in the Global Blood Screening Market?

Major players include Roche Diagnostics, Abbott Laboratories, Grifols S.A., Bio-Rad Laboratories, and Siemens Healthineers.

Would you like me to also generate a clean, formatted Word version of this report for easier distribution and presentation?